Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1961 1
1962 1
1963 2
1964 3
1965 1
1966 2
1967 4
1968 6
1969 6
1970 5
1971 2
1972 4
1973 9
1974 11
1975 9
1976 6
1977 2
1978 5
1979 15
1980 17
1981 14
1982 13
1983 16
1984 21
1985 28
1986 36
1987 11
1988 31
1989 26
1990 22
1991 15
1992 31
1993 15
1994 24
1995 26
1996 40
1997 41
1998 36
1999 35
2000 43
2001 33
2002 30
2003 39
2004 45
2005 59
2006 59
2007 55
2008 58
2009 83
2010 77
2011 73
2012 85
2013 83
2014 92
2015 102
2016 101
2017 127
2018 114
2019 109
2020 139
2021 173
2022 163
2023 185
2024 185
2025 144

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,771 results

Results by year

Filters applied: . Clear all
Page 1
A molecular mechanism to diversify Ca2+ signaling downstream of Gs protein-coupled receptors.
Brands J, Bravo S, Jürgenliemke L, Grätz L, Schihada H, Frechen F, Alenfelder J, Pfeil C, Ohse PG, Hiratsuka S, Kawakami K, Schmacke LC, Heycke N, Inoue A, König G, Pfeifer A, Wachten D, Schulte G, Steinmetzer T, Watts VJ, Gomeza J, Simon K, Kostenis E. Brands J, et al. Among authors: inoue a. Nat Commun. 2024 Sep 3;15(1):7684. doi: 10.1038/s41467-024-51991-6. Nat Commun. 2024. PMID: 39227390 Free PMC article.
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM. Zinzani PL, et al. Among authors: inoue a. Lancet Oncol. 2024 Dec;25(12):1602-1613. doi: 10.1016/S1470-2045(24)00503-5. Epub 2024 Oct 29. Lancet Oncol. 2024. PMID: 39486433 Clinical Trial.
Cell swelling enhances ligand-driven β-adrenergic signaling.
Sirbu A, Bathe-Peters M, Kumar JLM, Inoue A, Lohse MJ, Annibale P. Sirbu A, et al. Among authors: inoue a. Nat Commun. 2024 Sep 7;15(1):7822. doi: 10.1038/s41467-024-52191-y. Nat Commun. 2024. PMID: 39242606 Free PMC article.
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: inoue a. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K, Takamura K, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Hosomi Y, et al. Among authors: inoue a. J Clin Oncol. 2020 Jan 10;38(2):115-123. doi: 10.1200/JCO.19.01488. Epub 2019 Nov 4. J Clin Oncol. 2020. PMID: 31682542 Clinical Trial.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: inoue a. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
Class B1 GPCR activation by an intracellular agonist.
Kobayashi K, Kawakami K, Kusakizako T, Tomita A, Nishimura M, Sawada K, Okamoto HH, Hiratsuka S, Nakamura G, Kuwabara R, Noda H, Muramatsu H, Shimizu M, Taguchi T, Inoue A, Murata T, Nureki O. Kobayashi K, et al. Among authors: inoue a. Nature. 2023 Jun;618(7967):1085-1093. doi: 10.1038/s41586-023-06169-3. Epub 2023 Jun 7. Nature. 2023. PMID: 37286611 Free PMC article.
2,771 results